GlassScriptPhysician profile
David S Ellman
NPI 1992818199
$2,602.04
in general payments reported to CMS, 2019-2025
23 companies · $397 in 2025
The $397 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $404 · 2021: $240 · 2022: $283 · 2023: $417 · 2024: $286 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $584.13 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $579.07 | 2022-2025 | |
| Therapeuticsmd, INC. | $541.66 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $144.26 | 2024-2025 | |
| Astellas Pharma US INC | $118.38 | 2023-2025 | Veozah |
| Myovant Sciences INC. | $95.48 | 2021-2022 | |
| Millicent US INC | $81.43 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Evofem Biosciences, INC. | $75.97 | 2021-2023 | Phexxi |
| Hologic Sales and Service, LLC | $73.79 | 2019-2025 | Thinprep 2000 Processor, Aptima |
| Sumitomo Pharma America, INC. | $49.79 | 2024 | Myfembree |
| Pfizer INC. | $27.70 | 2019-2023 | |
| Biogen, INC. | $25.94 | 2025 | Zurzuvae |
| Vertical Pharmaceuticals, LLC | $25.66 | 2019 | |
| Medtronic, INC. | $25.00 | 2021 | |
| Ge Healthcare | $20.53 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $20.19 | 2019 | |
| Mission Pharmacal Company | $19.46 | 2020 | |
| Exeltis, USA INC. | $19.23 | 2023 | Tyblume |
| Organon LLC | $19.04 | 2023 | Nexplanon |
| Coopersurgical, INC. | $15.11 | 2023 | Summit Doppler |
| Zyla Life Sciences, INC. | $15.07 | 2020 | |
| Dysis Medical, INC. | $13.12 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ellman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.